Point72 Asset Management
KZIA

Point72 Asset Management’s Kazia Therapeutics KZIA Stock Holding History

Point72 Asset Management’s Portfolio KZIA Stock Details KZIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.49M Hold
200,000
– – ﹤0.01% 2506
2025
Q4 		$1.38M Buy
+200,000
New +$1.7M ﹤0.01% 2696

Other funds holding KZIA

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $6.71B AUM 23.99% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Point72 Asset Management's KZIA Position: Q1 2026 in Review

Point72 Asset Management held its Kazia Therapeutics (KZIA) position steady in Q1 2026 at 200,000 shares worth $1.49M. The position accounts for ﹤0.01% of the portfolio, ranked #2506.

Point72 Asset Management first reported a position in KZIA in Q4 2025 and has held it in 2 quarters since. 23 funds tracked by Wall St. Rank hold KZIA as of Q1 2026.

  • Point72 Asset Management held 200,000 shares of Kazia Therapeutics worth $1.49M as of Q1 2026.
  • Point72 Asset Management left its Kazia Therapeutics share count unchanged in Q1 2026.
  • Kazia Therapeutics made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #2506 holding.
  • Point72 Asset Management first reported a position in Kazia Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 23 funds tracked by Wall St. Rank held Kazia Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.